These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 6090180)

  • 1. Effects of SQ 27,427, a thromboxane A2 receptor antagonist, in the human platelet and isolated smooth muscle.
    Harris DN; Greenberg R; Phillips MB; Michel IM; Goldenberg HJ; Haslanger MF; Steinbacher TE
    Eur J Pharmacol; 1984 Aug; 103(1-2):9-18. PubMed ID: 6090180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 9 alpha-homo-9,11-epoxy-5,13-prostadienoic acid analogues: specific stable agonist (SQ 26, 538) and antagonist (SQ 26, 536) of the human platelet thromboxane receptor.
    Harris DN; Phillips MB; Michel IM; Goldenberg HJ; Heikes JE; Sprague PW; Antonaccio MJ
    Prostaglandins; 1981 Aug; 22(2):295-307. PubMed ID: 6270744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of prostaglandin biosynthesis by SQ 28,852, a 7-oxabicyclo[2.2.1]heptane analog.
    Harris DN; Phillips MB; Michel IM; Goldenberg HJ; Steinbacher TE; Ogletree ML; Hall SE
    Prostaglandins; 1986 Apr; 31(4):651-67. PubMed ID: 3088677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane receptor antagonist properties of SQ 27,427 in the anesthetized guinea pig.
    Greenberg R; Steinbacher TE; Harris DN; Haslanger MF
    Eur J Pharmacol; 1984 Aug; 103(1-2):19-24. PubMed ID: 6090175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of a new potent and specific thromboxane receptor antagonist (SQ-29,548) in vitro and in vivo.
    Darius H; Smith JB; Lefer AM
    J Pharmacol Exp Ther; 1985 Nov; 235(2):274-81. PubMed ID: 2997428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
    Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA
    J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics.
    Armstrong RA; Jones RL; MacDermot J; Wilson NH
    Br J Pharmacol; 1986 Mar; 87(3):543-51. PubMed ID: 3026540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
    Johnson GJ; Dunlop PC; Leis LA; From AH
    Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro.
    O'Keefe EH; Liu EC; Greenberg R; Ogletree ML
    Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
    de Chaffoy de Courcelles D; De Clerck F
    Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings.
    Terashita Z; Imura Y; Nishikawa K
    J Lipid Mediat Cell Signal; 1996 Jan; 13(1):1-8. PubMed ID: 8821806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
    Naka M; Mais DE; Morinelli TA; Hamanaka N; Oatis JE; Halushka PV
    J Pharmacol Exp Ther; 1992 Aug; 262(2):632-7. PubMed ID: 1386885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboxane A2 and prostaglandin endoperoxide receptors in platelets and vascular smooth muscle.
    Saussy DL; Mais DE; Knapp DR; Halushka PV
    Circulation; 1985 Dec; 72(6):1202-7. PubMed ID: 2998641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
    Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM
    J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.